4.4 All-cause mortality Mortality data was pooled from all four studies and sotatercept showed a trend toward reduced mortality (OR 0.63; 95 % CI 0.33–1.20).
← all excerpts
Efficacy and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized controlled trials.
3
—
—
The sentences
4.7 Serious adverse events (SAEs) Sotatercept was associated with a statistically borderline significant reduction in the incidence of SAEs (OR 0.72; 95 % CI 0.53–0.99) ( Fig. 4 A).
The pooled analysis for all-cause mortality showed a favorable trend (OR 0.63), however the confidence interval (0.33–1.20) crossed unity, indicating the data remains underpowered to confirm statistical significance for mortality as a stand-alone endpoint.